Vertex Pharmaceuticals
VRTX
515.02
-5.64
-1.08%
Vertex Pharmaceuticals
US · VRTX
#155 by market cap
Listed 1970
515.02
-5.64
-1.08%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 32 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 96.94% +0.00pp
- Institutions
- 2,129 +32
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund86.48%
Public Company3.21%
Hedge Fund1.90%
Government Pension Fund1.87%
Private Company1.36%
Sovereign Wealth Fund1.26%
Insurance Company0.31%
Individual/Insider0.20%
Family Office/Trust0.18%
Other3.22%
Top holders as of 2026-06-30
Capital Research
20.05% · 50.81M sh
BlackRock
9.51% · 24.11M sh
Vanguard Capital Management, LLC
7.10% · 18.01M sh
State Street Global Advisors
4.68% · 11.87M sh
Invesco Capital Management LLC
2.93% · 7.43M sh
Other
55.72%
Geode Capital Management, LLC
2.40% · 6.08M sh
J.P. Morgan Asset Management, Inc.
2.12% · 5.38M sh
Vanguard Portfolio Management, LLC
1.92% · 4.88M sh
Loomis, Sayles & Company L.P.
1.55% · 3.92M sh
UBS Asset Management
1.50% · 3.80M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 28 buys · 22 sells
| Name | Role | Stake |
|---|---|---|
| Amit Sachdev | Executive VP & Chief Patient and External Affairs Officer | 0.03% |
| Stuart Arbuckle | Former Chief Operating Officer | 0.03% |
| Ourania Tatsis | Executive VP & Chief Product Affairs Officer | 0.02% |
| Reshma Kewalramani | Chief Executive Officer | 0.02% |
| Bruce Sachs | Lead Independent Director | 0.02% |
| Jeffrey Leiden | Executive Chairperson | 0.01% |
| David Altshuler | Former Officer | 0.01% |
| Charles Wagner | Chief Operating Officer | 0.01% |
| Joy Liu | EVP, Chief Legal Officer & Corporate Secretary | 0.01% |
| Edward Atkinson | EVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-11 | Charles Wagner | Chief Operating Officer | Intent to Sell (Form 144) | -15,286 | $547.87 |
| 2026-11-05 | Reshma Kewalramani | Chief Executive Officer | Open Market Disposition | -11,866 | $531.53 |
| 2026-10-19 | Daniel Brennan | Independent Director | Other Acquisition | +795 | $503.47 |
| 2026-10-14 | Bruce Sachs | Lead Independent Director | Other Derivative Acquisition | +92 | -- |
| 2026-10-14 | Alan Garber | Independent Director | Other Derivative Acquisition | +29 | -- |
| 2026-09-07 | Jasper van Grunsven | Executive VP & Chief Pain & New Product Planning Officer | Other Acquisition | +8,682 | -- |
| 2026-08-27 | Kristen Ambrose | Chief Accounting Officer | Other Acquisition | +5,000 | -- |
| 2026-08-26 | Bruce Sachs | Lead Independent Director | Other Disposition | -6,000 | -- |
| 2026-07-20 | Amit Sachdev | Executive VP & Chief Patient and External Affairs Officer | Other Acquisition | +8,251 | -- |
| 2026-07-20 | Ourania Tatsis | Executive VP & Chief Product Affairs Officer | Other Acquisition | +8,251 | -- |
| 2026-07-14 | Bruce Sachs | Lead Independent Director | Other Derivative Acquisition | +99 | -- |
| 2026-07-14 | Alan Garber | Independent Director | Other Derivative Acquisition | +31 | -- |
| 2026-07-01 | Ourania Tatsis | Executive VP & Chief Product Affairs Officer | Automatic Disposition | -1,500 | $524.99 |
| 2026-07-01 | Duncan McKechnie | Executive Vice President | Automatic Disposition | -1,541 | $519.00 |
| 2026-06-30 | Joy Liu | EVP, Chief Legal Officer & Corporate Secretary | Automatic Disposition | -828 | $502.71 |
| 2026-06-25 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -596 | $482.50 |
| 2026-06-17 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -1,020 | $462.17 |
| 2026-06-14 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -4,062 | $450.00 |
| 2026-06-04 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -1,745 | $450.00 |
| 2026-05-31 | Joy Liu | EVP, Chief Legal Officer & Corporate Secretary | Automatic Disposition | -828 | $439.91 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:21 · For reference only, not investment advice and not tailored to your situation.
Vertex Pharmaceuticals discussion 0 comments